Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: Results of two 52-week, Phase III, randomized, placebo-controlled trials (INPULSIS™)
暂无分享，去创建一个
H. Collard | G. Raghu | H. Taniguchi | M. Selman | K. Brown | K. Flaherty | Y. Inoue | L. Richeldi | V. Cottin | D. S. Kim | M. Kolb | R. Schlenker‐Herceg | U. Costabel | A. Azuma | P. Noble | B. Disse | R. Bois | M. Brun | M. Girard